Sonnet BioTherapeutics Holdings, Inc. (SONN): Price and Financial Metrics
SONN Price/Volume Stats
| Current price | $3.07 | 52-week high | $66.00 |
| Prev. close | $3.21 | 52-week low | $3.02 |
| Day low | $3.02 | Volume | 50,200 |
| Day high | $3.30 | Avg. volume | 103,926 |
| 50-day MA | $6.33 | Dividend yield | N/A |
| 200-day MA | $13.05 | Market Cap | 5.38M |
SONN Stock Price Chart Interactive Chart >
SONN POWR Grades
- Growth is the dimension where SONN ranks best; there it ranks ahead of 95.23% of US stocks.
- SONN's strongest trending metric is Value; it's been moving up over the last 179 days.
- SONN's current lowest rank is in the Stability metric (where it is better than 2.31% of US stocks).
SONN Stock Summary
- Revenue growth over the past 12 months for SONNET BIOTHERAPEUTICS HOLDINGS INC comes in at -77.52%, a number that bests merely 2.34% of the US stocks we're tracking.
- In terms of volatility of its share price, SONN is more volatile than 98.57% of stocks we're observing.
- SONNET BIOTHERAPEUTICS HOLDINGS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -370.25%, greater than the shareholder yield of only 1.69% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to SONNET BIOTHERAPEUTICS HOLDINGS INC, a group of peers worth examining would be BNTC, IKT, GNFT, BLPH, and BNOX.
- Visit SONN's SEC page to see the company's official filings. To visit the company's web site, go to www.sonnetbio.com.
SONN Valuation Summary
- SONN's price/earnings ratio is -0.3; this is 101.1% lower than that of the median Healthcare stock.
- Over the past 206 months, SONN's price/sales ratio has gone down 168.3.
Below are key valuation metrics over time for SONN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SONN | 2023-09-18 | 35.8 | 1.8 | -0.3 | 0 |
| SONN | 2023-09-15 | 36.4 | 1.8 | -0.3 | 0 |
| SONN | 2023-09-14 | 37.0 | 1.9 | -0.3 | 0 |
| SONN | 2023-09-13 | 38.2 | 1.9 | -0.3 | 0 |
| SONN | 2023-09-12 | 39.9 | 2.0 | -0.3 | 0 |
| SONN | 2023-09-11 | 37.6 | 1.9 | -0.3 | 0 |
SONN Growth Metrics
- Its year over year cash and equivalents growth rate is now at 102.34%.
- Its 3 year price growth rate is now at -99.24%.
- The 5 year cash and equivalents growth rate now stands at 97.71%.
The table below shows SONN's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 0.257399 | -25.5101 | -29.063 |
| 2022-09-30 | 0.349943 | -27.68728 | -29.72184 |
| 2022-06-30 | 0.770816 | -27.46372 | -29.23857 |
| 2022-03-31 | 0.708745 | -25.48387 | -27.47709 |
| 2021-12-31 | 0.613425 | -25.66291 | -25.3077 |
| 2021-09-30 | 0.483626 | -22.55224 | -24.98396 |
SONN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SONN has a Quality Grade of D, ranking ahead of 9.63% of graded US stocks.
- SONN's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
- QGEN, ALNY, and RDUS are the stocks whose asset turnover ratios are most correlated with SONN.
The table below shows SONN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.000 | NA | 6.121 |
| 2021-03-30 | 0.000 | NA | 8.723 |
| 2020-12-31 | 0.492 | 0.045 | -7.708 |
| 2020-09-30 | 0.000 | NA | -2.244 |
| 2020-06-30 | 0.549 | 0.025 | -1.292 |
| 2020-03-31 | 0.683 | 0.039 | -0.581 |
SONN Price Target
For more insight on analysts targets of SONN, see our SONN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $6.50 | Average Broker Recommendation | 1.25 (Strong Buy) |
Sonnet BioTherapeutics Holdings, Inc. (SONN) Company Bio
Sonnet BioTherapeutics Holdings, Inc. operates as a clinical stage biotechnology company. The Company develops fully human albumin binding technology that helps the development of innovative targeted biologic drugs with enhanced single-or bi-specific mechanisms. Sonnet BioTherapeutics Holdings serves customers in the United States.
Latest SONN News From Around the Web
Below are the latest news stories about SONNET BIOTHERAPEUTICS HOLDINGS INC that investors may wish to consider to help them evaluate SONN as an investment opportunity.
Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB TechnologySonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced data from two radiolabeling studies that validate the tumor targeting attributes associated with albumin binding by the FHAB technology. |
Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price ComplianceSonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has received formal notice from the Listing Qualifications staff of The Nasdaq Stock Market indicating that Sonnet has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). |
Sonnet BioTherapeutics Announces 1-for-22 Reverse Stock SplitSonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-22 reverse stock split of its outstanding common stock. |
7 F-Rated Biotech Stocks You Shouldn’t Touch With a 10-Foot PoleThere are some solid biotech stocks on the market. |
Sonnet BioTherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the USSonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the IND for SB221 (NCT05756907), the Phase 1b/2a clinical trial of SON-1010(IL12-FHAB) in combination with Roche's anti-PD-L1 checkpoint inhibitor, atezolizumab, has been accepted, and the study can begin in the US for the treatment of PROC. |
SONN Price Returns
| 1-mo | -51.88% |
| 3-mo | -79.32% |
| 6-mo | -58.09% |
| 1-year | -91.33% |
| 3-year | -99.59% |
| 5-year | -99.98% |
| YTD | -87.87% |
| 2022 | -80.12% |
| 2021 | -81.48% |
| 2020 | -85.46% |
| 2019 | -54.26% |
| 2018 | -50.95% |
Loading social stream, please wait...